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ABSTRACT
In this study we present a new diagnostic workup for the myelodysplastic 
syndromes (MDS) including FISH, aCGH, and somatic mutation assays in addition 
to the conventional cytogenetics (CC). We analyzed 61 patients by CC, FISH for 
chromosome 5, 7, 8 and PDGFR rearrangements, aCGH, and PCR for ASXL1, EZH2, 
TP53, TET2, RUNX1, DNMT3A, SF3B1 somatic mutations. Moreover, we quantified 
WT1 and RPS14 gene expression levels, in order to find their possible adjunctive 
value and their possible clinical impact. CC analysis showed 32% of patients with 
at least one aberration. FISH analysis detected chromosomal aberrations in 24% of 
patients and recovered 5 cases (13.5%) at normal karyotype (two 5q- syndromes, 
one del(7) case, two cases with PDGFR rearrangement). The aGCH detected 10 “new” 
unbalanced cases in respect of the CC, including one with alteration of the ETV6 
gene. After mutational analysis, 33 patients (54%) presented at least one mutation 
and represented the only marker of clonality in 36% of all patients. The statistical 
analysis confirmed the prognostic role of CC either on overall or on progression-free-
survival. In addition, deletions detected by aCGH and WT1 over-expression negatively 
conditioned survival. In conclusion, our work showed that 1) the addition of FISH 
(at least for chr. 5 and 7) can improve the definition of the risk score; 2) mutational 
analysis, especially for the TP53 and SF3B1, could better define the type of MDS and 
represent a “clinical warning”; 3) the aCGH use could be probably applied to selected 
cases (with suboptimal response or failure).
INTRODUCTION
Myelodysplastic syndromes (MDS) are a 
heterogeneous group of hematological disorders which 
involve hypercellular and dysplastic bone marrow (BM) 
and different grades of cytopenias in the peripheral blood 
(PB) [1]. The majority of patients affected by MDS are 
diagnosed during routine blood tests; symptoms of MDS 
are often secondary to the peripheral cytopenias caused 
by the bone marrow failure [2]. At the basis of diagnosis, 
is still today the cyto-morphological analysis of the PB as 
well as of BM and the bone marrow biopsy performance. 
The World Health Organization (WHO) recently revisited 
the MDS classification [3, 4], defining different entities 
according to the number of involved lineages (single or 
multiple), the presence of ring sideroblasts ( > 15% or < 
5% in presence of the SF3B1 mutations), and the blasts’ 
percentage. Moreover, also this classification does not still 
offer prognostic information, and thus different prognostic 
system scores help physicians to make correct therapeutic 
decisions. The international prognostic scoring system 
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(IPSS) is still the most used prognostic tool, but a dynamic 
system score (WPSS) and the revised IPSS (R-IPSS) are 
also now available [2-5-6].
Conventional karyotyping continues to have a 
fundamental role in the classification and prognostication 
of MDS. Indeed, more than half of MDS patients present 
with one or more chromosomal aberrations; nevertheless, 
non-informative karyotypes still concern up to 20% of 
cases [7]. The integration of fluorescent hybridization 
in situ (FISH) allowed a more accurate definition of the 
chromosomal abnormalities offering the advantage of 
analyzing cells in interphase, but its role in the diagnostics 
of MDS it has not yet been well defined. First comparisons 
of cytogenetics and FISH indicated a role for FISH in 
facilitating MDS diagnosis and prognostication [8, 9]; 
nevertheless, other studies demonstrated an overlapping 
between conventional cytogenetics (CC) and FISH 
results, reserving the FISH analysis to those cases where 
karyotype failed [10].
In this complex scenario, the contribution of array 
CGH (Comparative Genomic Hybridization, aCGH) 
can overcome some of the limitations of the cytogenetic 
techniques: this method does not rely on cell division, 
has superb resolution for unbalanced lesions, and allows 
defining the copy number variation. Recent genome-
wide microarray-based studies demonstrated a relevant 
frequency of submicroscopic copy number alterations 
in MDS, demonstrating that aCGH would be a potential 
method to detect cryptic relevant genomic markers [11, 
12] revealing chromosomal aberrations in 80% of cases 
defined as “normal” by CC and FISH [13].
Another recent field of interest is the identification 
of somatic mutations, reported in a large variety of de 
novo MDS, including cases with normal cytogenetics 
[14]. Particular relevance had EZH2, ASXL1, DNMT3A, 
IDH1/IDH2, SF3B1, TP53, and TET2; TET2 mutations 
were associated with better responses to 5-azacitidine 
[15]; ASXL1, EZH2, TP53, and DNMT3A mutations 
have been associated to worse outcome [16-18]. IDH1 
and IDH2 mutations have been reported to impair the 
prognosis of patients with acute leukemia [19], but in 
MDS the prognosis seems to be not different [20]. In a 
large series of young patients affected by AML, Patel 
et al. identified at least one somatic alteration in 97.3% 
of them: FLT3-ITD, MLL partial tandem duplication, 
and ASXL1 mutations were associated with reduced OS, 
whereas CEBPA and IDH2 mutations were associated with 
improved OS. Interestingly, the favorable effect of NPM1 
mutations was restricted to patients with co-occurring 
IDH1 or IDH2 mutations [21].
On these basis, in the present study we set an 
integrated cytogenetic/molecular workup for the diagnosis 
of MDS in order to by-pass possible diagnostic failures 
and to increase the prognostic power of the today available 
diagnostic tools.
Thus, we screened 61 MDS patients for somatic 
mutations (TET2, TP53, ASXL1, EZH2, RUNX1, 
DNMT3A, SF3B1) by Real-Time PCR, in addition to the 
CC, FISH analysis, and aCGH. Finally, we performed 
quantitative RT-PCR assays to quantify the expression of 
two genes already known as prognostic in MDS: WT1 and 
RPS14. The WT1 (Wilms’ tumor) is a tumor suppressor 
gene [22] whose over-expression well correlates with 
blasts percentage [23, 24]. RPS14 codifies for a ribosomal 
subunit; its haplo-insufficiency appeared to be responsible 
for the anemia in the 5q- syndrome [25], even if a reduced 
expression was also found in 71% of patients with an 
intermediate-1 IPSS risk without 5q- aberration [26].
Our results suggest the addition of some selected 
FISH and mutational assays in the diagnostic workup 
of MDS; probably, aCGH would be reserved to selected 
cases (where the CC fails or to resistant cases).
RESULTS
Patients
Clinical features of the 61 enrolled MDS patients are 
reported in the Table 1.
According to the IPSS score, 67% of cases resulted 
at low/intermediate-1 and 26% at intermediate-2/high, 
while according to the R-IPSS 49% were at very-low/low, 
33% at intermediate, and 18% at high/very-high risk.
Conventional cytogenetics
CC analysis was performed in all patients; in 12% 
of them it was not possible to analyze 20 metaphases, so 
CC failed. CC analysis documented in 32% of patients 
at least one chromosomal aberration, such as trisomy of 
chromosome 8 (in 9% of cases), deletion of chromosome 
5 (in 4%), of chromosome 7 (in 2%) or of the Y (in 2%). 
Complex karyotype was found in 7% of patients, and 
in single cases deletion of chromosome 13, duplication 
of chromosome 14, t(9;12) (q32;q12), and trisomy of 
chromosome 6 have been observed. Overall, these results 
significantly correlated with the WHO classification: 87% 
of the forms with excess of blasts presented an abnormal 
karyotype, followed by the unilineage cytopenia with ring 
sideroblasts (40%), and by the multi-lineage cytopenias 
(27%). All patients with unilineage cytopenia (previously 
classified as refractory anemia) had a normal karyotype.
FISH
FISH for chromosomes 5, 7, 8 and PDGFR 
rearrangements was performed in all patients with normal 
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karyotype and in the cases who failed CC, in order to 
identify eventual “new” chromosomal aberrations. In 
cases with abnormalities of chromosome 5, 7 or 8 at the 
CC, FISH was used for confirming results. FISH analysis 
failed in only 2 cases, and it was not be deliberately 
performed in the 4 cases with complex karyotype; thus, 
its applicability resulted of 96.5% versus 88% of the 
CC. FISH results were available for the 37 patients with 
normal karyotype; in 5 cases (13.5%) FISH allowed us 
identifying a new chromosomal abnormality: in 2 cases a 
5p15.2-q31 deletion, in one a deletion of chromosome 7, 
and in other 2 patients a PDGFRB rearrangement. In these 
cases, in order to exclude a myeloid disorder with PDGFR 
rearrangement, a PCR for the PDGFRB-ETV6 fusion gene 
was performed, but it resulted negative. In cases where 
the FISH analysis was adopted for confirming the results 
from the CC, a full concordance was observed. Overall, by 
adding the chromosomal abnormalities detected by FISH 
to those already shown by CC, the 51% of our patients 
presented at least one chromosomal aberration.
aCGH
aCGH analysis was performed in 59 patients; in 
the 2 remaining cases it failed for insufficient available 
DNA. Overall, copy number changes were identified 
in 23 cases (39%): 14 showed deletions involving 
chromosomes 3, 5, 7, 8, 11, 12, 13, 16, 17, and 20, and 
one patient presented loss of chromosome Y. Three cases 
harbored gains of chromosome 8, and other 3 showed a 
duplication of chromosome 1, 3, and 14, respectively. 
The last two cases harbored a complex karyotype: one 
involved chromosomes 1, 4, 7, 17 and 21, and the other 
one showed a deletion of 16q23.2 added to a mosaic of 
two different mutation of chromosome 11. In 13 patients, 
aCGH confirmed the cytogenetic analyses (4 and 5 cases 
confirmed the CC and FISH results, respectively); in the 
10 remaining cases (43.5%), already defined as “normal”, 
aCGH identified “new” copy number alterations (Table 2). 
Interestingly, the 12p13.2 breakpoint fell into the ETV6 
gene, which results partially deleted; this type of deletion 
has been detected in a broad spectrum of hematological 
malignancies, frequently with monosomy 7, such as in our 
case [27]. All comparative results are reported in Table 3.
Somatic point mutation analysis
Somatic point mutations analysis for TET2, EZH2, 
TP53, ASXL1, SF3B1, RUNX1, DNMT3A was performed 
in all cases; 33 patients (54%) presented at least one 
mutation. The more frequent mutations resulted TP53 
in 18 cases (29.5%) and SF3B1 in 12 patients (19.7%). 
ASXL1 was mutated in 5 patients (8%), TET2 in 2 cases 
(3.3%), RUNX1 in only one case (1.6%), and no cases 
showed DNMT3A or EZH2 mutations. In the cohort of 
patients with normal karyotype, TP53 was mutated in 
25% of them, SF3B1 in 22%, ASXL1 in 11%, TET2 and 
RUNX1 in 2.7% of cases. 
TP53 mutation interested 29.4% of the multi-lineage 
cytopenias, 26.7% of the forms with excess of blasts, 25% 
of the 5q-, and 23.5% of the unilineage cytopenia and 
chronic myelo-monocytic leukemia. Ten of the 12 patients 
with ring sideroblasts (83.3%) presented the SF3B1 
mutation; in 5 cases (41.6%), SF3B1 was concomitant to 
the TP53 mutation. In the remaining cases, mutations were 
exclusive.
Figure 1: Poor karyotype negatively conditioned OS.
Oncotarget79191www.impactjournals.com/oncotarget
No correlation were observed between somatic 
mutations and risk scores, except for the SF3B1 that was 
mutated in 30% of the cases in the low/very low vs 20% 
in the high/very high risk WPSS category (p = 0.048). 
No differences in respect of age or sex were found. In 
3 of our patients, a different neoplasia was reported; in 
these cases, we cannot be sure that the mutation detected 
was really somatic and not the expression of a germ-
line predisposition; unfortunately, no fibroblasts or other 
somatic sources were available for comparison.
Figure 2: The presence of chromosomal deletions, detected by array CGH, negatively conditioned OS (OS:30-months; 
p=0.04).
Table 1: Clinical features of enrolled patients.
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WT1 and RPS14 gene expression
The WT1 results were expressed as WT1 copies/ABL 
x 104 copies and the normal ratio was considered from 3 to 
180 copies. Patients with high WT1 expression were 28% 
of the all patients, with a value ranging from 242 to 3395. 
RPS14 quantitative results were normalized and 
expressed as RPS14/18S copies ratio. The statistical 
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11 previously identified 
cases
5 “new detected” 
cases
10 “new detected” 
cases 22 “new detected” cases
Figure 3: WT1 high levels predicted shorter OS.
Table 2: Chromosomal “new”abnormalities detected by CGH array.
Oncotarget79193www.impactjournals.com/oncotarget
analysis was performed stratifying samples in “low” 
and “high” respect to the median values measured in the 
healthy donors (median = 1,073). The majority of cases 
showed low levels of RPS14 gene expression, while the 
high-level cases were 11% of the all patients (range 1.07-
1.47). 
WT1 or RPS14 expression did not differ according 
to the karyotype (normal vs abnormal), IPSS, WPSS 
or R-IPSS scores. Moreover, there was not correlation 
between genes’ expression values and somatic mutation; 
on the contrary, higher WT1 levels were found in patients 
with chromosomal deletions shown by aCGH in respect of 
no deleted cases (58.3% vs 18.7%; p = 0.023). 
Clinical outcome
Overall, 52 patients were enrolled concomitantly to 
the diagnosis of MDS, whereas in other 9 the diagnosis 
of MDS has been performed previously, with a median 
interval of 32 months (range: 11-56 months) to the 
accrual. In these cases, cytogenetic and molecular analyses 
were performed in occasion of a routine bone marrow 
assessment. 
With a median follow-up of 21 months (range: 
8-41), 67% of patients were still alive at 30 months; when 
patients were stratified on the basis of treatment, median 
OS was 33 months for patients receiving erythropoietin 
(Epo), granulocyte stimulating factor (G-CSF) or 
supportive care, compared to 37 months for those treated 
with azacitidine, and 21 months for patients affected 
by chronic myelomonocytic leukemia (CMML) or 5q- 
syndrome that received hydroxyurea or lenalidomide. 
These observed differences were not statistically 
significant.
Progression-free-survival (PFS) was calculated from 
the eighth week of treatment with Epo or from the forth 
month of therapy with azacitidine in cases with stable 
disease or from the date of best response (for responsive 
cases) until the day of progression into acute leukemia. 
If deaths occurred for causes not disease-related, patients 
were considered as “progression free”. For the entire 
series, median PFS was not reached during the observation 
interval; at 30 months, 78% of patients still did not 
progress. When patients were stratified on the basis of 
treatment, 30-months PFS was 85% for patients receiving 
erythropoietin or G-CSF or supportive care, versus 87% 
of those treated with azacitidine, versus 55% of patients 
receiving hydroxyurea or lenalidomide. As for OS, also 
these differences were not significant. 
On the contrary, median OS was longer for patients 
achieving a good response [hematological improvement 
(HI), partial (PR) or complete response (CR)] after 
treatment in comparison to those with stable (SD) or 
progressive disease (PD) (44 versus 28 months; p = 
0.015). Also the percentage of blasts measured in the bone 
marrow smears at the enrollment was predictive of OS: 
patients carrying ≥10% blasts showed a shorter median OS 
(18 months versus 41; p = 0.009). 
Then, OS was analyzed according to the IPSS, 
Figure 4: High WT1 expression played a negative impact on PFS.
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WPSS, and R-IPSS risk scores: IPSS and WPSS were 
able to significantly categorize the different risk groups 
also in our series (p = 0.03; p = 0.01); about R-IPSS, 
the statistical power was not reached (p = 0.12), even if 
a trend for a shorter survival was observed for high and 
very-high risk patients. 
When we analyzed the OS probability on the basis 
of karyotype risk (23% or 21% with poor karyotype 
according to the IPSS or the R-IPSS scores), cases with 
higher cytogenetic risk showed a shorter OS (median = 11 
months versus 33 with IPSS score: p = 0.02; 10 months 
versus 34 with R-IPSS score: p = 0.02) (Figure 1).
The presence of chromosomal aberration detected 
by CC or by FISH did not impact on OS. 
The presence/absence of whatever abnormality 
found by aCGH did not change OS; on the contrary, 
30-months OS was 57% for patients showing a deletion 
shown by aCGH versus 83% of not deleted patients (p = 
0.04) (Figure 2). 
When we analyzed the impact of deletions 
detected by aCGH according to the karyotype (normal 
vs abnormal), we found that the 30-months OS was 85% 
for cases with normal karyotype/no deletions by aCGH 
vs 54% for those with normal karyotype plus deletions; 
nevertheless, this difference of 31% did not reach the 
statistical significance (p = 0.30). On the contrary, in the 
subgroup with abnormal karyotype, the 18-months OS (in 
this cohort the median follow-up was shorter) was 100% 
for cases without deletions by aCGH vs 50% for those 
with deletions; this difference was significant (p = 0.025), 
thus suggesting that a particular attention (and then a more 
strict follow-up) has to be done in cases with deletions 
detected by aCGH, especially in cases with abnormal 
karyotype.
When Real-Time PCR tests were performed in 
order to find gene mutations, the OS analysis between 
mutated and wild-type patients did not detect significant 
differences, neither in the subgroup with normal, nor 
in that with abnormal karyotype. Only in the cohort 
with normal karyotype, the SF3B1 mutations positively 
conditioned the 30-months PFS, even if without statistical 
significance (100% for mutated cases vs 79% for the wild-
type ones; p = 0.22). 
Finally, OS was evaluated according to WT1 and 
RPS14 values; at the enrollment, 70% of all patients 
showed RPS14 values lower than those measured in 
healthy donors; on the other hand, 28% carried higher WT1 
levels. RPS14 expression levels did not condition median 
OS; on the contrary, OS resulted shorter for cases showing 
high WT1 values (18 months versus 41; p = 0.001) (Figure 
3). The high WT1 expression levels maintained a statistical 
significance also in multivariate analysis, including blasts 
number, quality of response, risk scores and chromosomal 
deletions (HR = 3.78; 95%CI = 1.9-1037; p = 0.018).
In the overall series, PFS was not significantly 
affected by sex, age > 65 years, or type of treatment, even 
if it resulted 16 months shorter for older patients in respect 
of the younger ones. On the contrary, 30 months-PFS 
was higher for patients achieving clinical response after 
treatment in comparison to those with stable or progressive 
disease (100% versus 67%; p = 0.002). Differently 
from that already observed for OS, ≥10% blasts did not 
significantly impact on PFS, even a trend for longer 
progression-free time was observed for cases with < 10% 
blasts (p = 0.06). The PFS was analyzed according to the 
IPSS, WPSS, and R-IPSS risk scores categories and only 
the WPSS score was able to significantly categorize the 
different risk groups (p = 0.01). When PFS was analyzed 
according to cytogenetic features, the presence/absence of 
chromosomal aberrations did not result significant. 
On the contrary, as expected, cases at higher 
cytogenetic risk, either classified according to the IPSS 
or the R-IPSS scores, showed a lower 30-months PFS 
rate (37% versus 83%; p = 0.01). Even when FISH results 
(molecular abnormalities present/absent) were computed, 
no differences in PFS were observed. 
Then, we analyzed the prognostic role of 
chromosomal abnormalities detected by aCGH; when 
the whole population was considered, no differences in 
PFS were observed. Then, as for the OS, we analyzed 
the impact of deletions detected by aCGH according to 
the karyotype (normal vs abnormal); we found that the 
30-months PFS was 86% for cases with normal karyotype/
no deletions by aCGH vs 71% for those with normal 
karyotype plus deletions; nevertheless, this difference of 
15% did not reach the statistical significance (p = 0.64). 
On the contrary, in the subgroup wit abnormal karyotype, 
the 18-months PFS was 100% for cases without deletions 
by aCGH vs 57% for those with deletions; this difference 
was at the limit of the statistical significance (p = 0.060).
When PFS was measured according to mutations 
detected by PCR (TET2, EZH2, TP53, ASXL1, SF3B1, 
DNMT3A, RUNX1), no significant differences were 
detected between the subgroup with normal and that with 
abnormal karyotype.
Finally, PFS was estimated according to the WT1 
and RPS14 values. As described for the analysis of the OS, 
RPS14 expression was not significant, whereas 30-months 
PFS rate resulted significantly lower for cases carrying 
WT1 higher values (56% versus 89%; p = 0.01) (Figure 4). 
When multivariate analysis was performed including 
quality or response, WPSS risk score, poor karyotype, and 
WT1 levels, none of the considered variables retained their 
prognostic significance.
DISCUSSION
As above reported, more than half of MDS cases 
present with abnormal karyotype; nevertheless, non-
informative karyotypes represent up to 20% of cases. In 
this way, the integration of molecular techniques (FISH, 
aCGH, PCR) are promising tools for a more accurate 
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definition of the chromosomal abnormalities and then for 
a more correct risk stratification. Thus, in our study 61 
MDS patients were analyzed of diagnosis by conventional 
cytogenetics, FISH, aCGH and mutational analysis by 
Real-Time PCR. 
As first finding, in our study a lower rate of CC 
failure was observed (only 12%); this low percentage 
of failures in comparison to rates reported in literature 
would depend from a more correct management of 
samples. Indeed, we used for cytogenetic analyses the 
bone marrow samples aspirated immediately after doing 
the bone marrow smears destined to the morphological 
assessment. Overall, 55% of our patients presented with 
chromosomal abnormalities (detected by CC and/or 
FISH). The relevance of conventional cytogenetic analysis 
in the clinical practice is evident also in our series: the 
high cytogenetic risk score was associated with a shorter 
OS (median: 11 months vs 33 according IPSS: p = 0.02; 10 
months versus 34 according R-IPSS: p = 0.02) and PFS (at 
30 months, 37% versus 83% free of progression into acute 
leukemia; p = 0.01). 
After the FISH analysis, five “new” chromosomal 
abnormalities were observed, thus recognizing to the 
FISH an additive value in respect of the CC analysis. 
In particular, FISH allowed us correctly classifying two 
patients with normal karyotype as affected by the 5q- 
syndrome; in another case, the identification of deletion 
of chromosome 7 allowed us inserting our patient into the 
poor cytogenetic risk group, so offering to them the correct 
treatment (lenalidomide and azacitidine, respectively). 
Finally, two patients presented the PDGRFbeta 
rearrangement, and thus they received imatinib, effective 
in MDS cases with PDGFR rearrangement in addition 
to the chronic myeloid leukemia [29]. Both patients 
maintained for several months a partial response and then 
underwent successfully to the allogeneic transplantation. 
Recently, the advantages of FISH for abnormalities 
of chromosome 8, 7, 5, 20, and Y in respect of CC has 
been reported in a very huge series by a Chinese group: 
conventional banding was successful in 94.0% of patients, 
whereas FISH resulted informative in 100% of cases. 
Interestingly, FISH identified abnormalities in 50% of 
cases where the CC failed, and in 24% of the patients 
exhibiting normal karyotype. Authors concluded that FISH 
had to be applied to cases where the CC failed or with a 
normal karyotype [30]. The advantage given by the FISH 
addition in the Chinese study was higher than that found 
in our cohort (8.7%), but it would be depend either from 
the very different number of patients (more than 2000 vs 
57) or from the fact that Chinese authors adopted also 
FISH for the chromosomal Y that we did not used. It is 
to be considered that this deletion can be detected in 5% 
of the healthy old male subjects [31], in cases affected by 
autoimmune disorders [32], neurodegenerative diseases 
[33], or neoplasia [34]. 
In conclusion, our results sustain what recently 
suggested by the European Leukemia Network, to add 
FISH in case of CC failure [4]; indeed, in our study we 
demonstrated that FISH analyses could represent an 
adjunctive value during the diagnostic phase of MDS, 
allowing us to correctly treat 3 cases.
About aCGH, we found chromosomal aberrations 
in the 17% of patients with normal karyotype, including 
two types of duplications and seven different losses of 
chromosomal regions. In particular, one case showed 
a partial deletion of 12p13.2 region in correspondence 
of the ETV6 gene, associated with a partial monosomy 
of chromosome 7. In this patient, aCGH confirmed the 
monosomy of chromosome 7 and detected a chromosome 
12p interstitial deletion not visible at the CC. Interestingly, 
the 12p13.2 breakpoint fell into the ETV6 gene, which 
resulted partially deleted; ETV6 is considered the main 
candidate tumor suppressor gene within this region [35-
36]. Our data about aCGH reflect those already published 
by other groups: in a recent study, aCGH detected copy 
number changes in 11% of MDS patients with normal 
CC; the authors described recurrent sub-microscopic 
deletions, which encompassed some genes involved 
in MDS prognosis, such as TET2 and ETV6 [37]. In 
our cohort, aCGH allowed us identifying two different 
cases with deletion of the long arm of the chromosome 
3 (one of these involving the GATA2 gene); to note that 
both patients had normal CC and FISH. Abnormalities 
involving chromosome 3q are not frequent in MDS, but 
they have been associated with poor cytogenetic risk and 
shorter OS [39]; interestingly, both our patients developed 
acute leukemia during the study. Moreover, another 
interesting finding is that the negative prognostic impact is 
reserved to the deletions only: while the presence/absence 
of whatever abnormality detected by aCGH did not 
impact on OS, 30-months OS was 57% for patients with 
deletions detected by aCGH versus 83% of those without 
abnormalities or aberrations different from deletions 
(p = 0.04). These results are perfectly in line with those 
published by Volkert et al. who reported that aCGH 
detected copy number changes in 11% of MDS patients 
with normal karyotype and that OS was significantly 
shorter in patients with deletions detected in comparison 
to cases without abnormalities or other changes detected 
by aCGH (median OS: 71 vs 43 months) [37]. 
Finally, the somatic mutation analysis of TP53, 
ASXL1, EZH2, TET2, RUNX1, DNMT3A and SF3B1 
genes allowed us identifying different mutations in 54% 
of patients; in 22 patients (36% of total) the molecular 
one was the only identified marker of clonality. In patients 
with MDS, mutations in TP53, EZH2, ETV6, RUNX1, 
and ASXL1 were found to be recurrent and to predict poor 
overall survival, independently of other established risk 
factors [38]. In our cohort, the more frequent somatic 
mutations included TP53 and SF3B1. 
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The TP53-mutated patients were principally in 
the low/intermediate-1 classes; one patient with ring 
sideroblastic anemia at low IPSS risk, with normal 
karyotype, FISH and aCG, presented SF3B1 and TP53 
mutations. Moreover, it is interesting to note that in 
our series we observed 3 patients TP53-mutated with 
a concomitant neoplasia. TP53 mutations have been 
reported also in many hematological and solid tumors, 
even with adverse outcome [39-41]. In line with this 
results, in our cohort TP53 mutations were detected in 3 
cases of MDS arising after chemotherapies for previous 
lymphoproliferative disorders, and in the half of MDS 
patients with complex karyotype. 
About the other molecular abnormalities found in 
our series, the number of the TET2-mutated patients is 
too small for deriving clinical conclusions; one patient 
well responded to azacitidine, as previously reported in 
literature [15], whereas the other one did not achieve 
satisfying results. Moreover, in our study 5 patients 
presented with ASXL1 mutations; the small number of 
cases does not allow us achieving significant statistical 
results about its prognostic role. The negative prognostic 
role of ASXL1 in acute and myeloproliferative disorders 
is now well recognized [42, 43], and the assessment of 
this gene mutations in the clinical practice could help 
physician to design from the diagnosis a patient-tailored 
treatment. 
Other interesting findings coming from our 
study concern the assessment of WT1 and RPS14 gene 
expression. At the time of diagnosis, 70% of patients 
showed RPS14 values lower than those measured in 
healthy donors, and 28% carried high WT1 levels. 
Interestingly, OS was shorter for cases showing WT1 
higher values (18 months versus 41; p = 0.001), in analogy 
to what occurred for 30-months PFS (56% versus 89%; 
p = 0.01). To note that the 38% of our patients with high 
expression of WT1 presented higher percentage of blasts, 
while 44% presented with cytogenetic alteration included 
in the intermediate and poor risk, as previously reported 
[24]. The negative impact of the WT1 expression levels on 
survival in perfectly in accordance with data published by 
Nagasaki et al. who reported a negative impact of WT1 
expression on OS in a series of old MDS patients (HR = 
6.4) [44].
Lower RPS14 expression in MDS patients without 
5q deletion was reported to be associated with increased 
apoptosis of nucleated erythrocytes; consequently, an 
up-regulation during treatment could be a positively 
predictor marker of response to lenalidomide [45]. In our 
series, low RPS14 levels were shown in more than 2/3 of 
patients. These data confirmed those from the literature, 
where reduced expression of RPS14 was described in 
71% of patients with intermediate IPSS risk in absence 
of chromosome 5 deletions [26]. Differently from these 
authors, who reported that PFS was positively conditioned 
by low RPS14 levels, in our cohort the RPS14 expression 
did not condition OS nor PFS even if a trend to longer 
PFS was observed in cases with low RPS14 expression 
(30 months-PFS: 100% versus 78%; p = 0.13) receiving 
azacitidine.
In conclusion, our study supports the idea that an 
integrated diagnostics (cytogenetic and molecular) workup 
could be useful for a better risk stratification of MDS 
patients. The number of cases enrolled in our study is 
surely small, but it is the mirror of the real-life lived in the 
majority of hematological centres, where the diagnostic 
assays have to be optimized also for the small number 
of cases/month. Indeed, even in our center we employ 
an advanced NGS platform for detecting mutations in 
myeloid disorders; nevertheless, the optimization of times 
and costs implies at least 15-20 cases/run. Sometimes 
physicians need rapid results for choosing ab initio the 
more correct treatment; we suggest that in these cases 
simple real-time PCR assays as those presented in this 
study could answer this clinical need, with acceptable 
costs and time. The addition of FISH can ameliorate the 
cytogenetic definition of the risk score, with sustainable 
costs. Finally, the aCGH could even better define the risk 
of progression into acute leukemia, but this technique 
could be probably applied to cases with suboptimal 
response or failure for re-defining or modifying the 
therapeutic project instead of to all patients at diagnosis.
PATIENTS AND METHODS
Patients
A total of 61 patients (18 women and 43 men), 
with a median age of 74 years (range 30-92 years), were 
enrolled at time of diagnosis during a routinary control at 
the Hematology Unit of Pisa, from June 2012 to March 
2015. All patients gave written informed consent for the 
use of their data for scientific evaluations. 
According to the WHO classification, 33% were 
affected by multilineage refractory cytopenias (RCMD), 
12% by refractory anemia (RA), 15% by refractory anemia 
with ring sideroblasts (RARS), 21% by refractory anemia 
with excess of blasts (RAEB 1-2), 3% by 5q- syndrome, 
and 12% by chronic myelo-monocytic leukemia (CMML).
Conventional cytogenetics
Chromosomes were QFQ banded and at least 20 
metaphases were analysed using standard procedures 
and karyotype was described, according to ISCN [28]. 
Structural chromosomal aberrations were considered if 
found in at least two metaphases. On the contrary, three 
complete metaphases presenting the same loss were 
required to diagnose a monosomy. Karyotype complexity 
(CK) was considered in accordance with Schanz et al 
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(Schanz et al., 2012) including non-CK ( < three CAs), 
sCK (three CAs), and very CK ( > three CAs). 
FISH analysis
FISH analysis was performed according to standard 
protocols. FISH color probe sets included: 5p15.2 (normal 
range; 0-4%)/EGR1 (5q31) (Abbott Molecular, Abbott 
Park, IL), CEP7 (normal range; 0-5%)/7q31 (0-7%), 
CEP8 (normal range; 0-7%), 5q32 (PDGFRb-Breakapart. 
Cytocell Celbio) (normal range;0-5%) and 4q12 (FIP1L1/
CHIC2/PDGFRa-deletion/fusion. Cytocell Celbio) 
(normal range; 0-5%). Thresholds for interpretation as 
a positive result were established for each probe at 3 
standard deviations above the mean of 20 normal bone 
marrow samples. 
aCGH analysis
After DNA extraction from 200 uL of whole bone 
marrow by the QIAamp DNA Blood Mini Kit (Qiagen, 
Hilden, Germany), oligonucleotide whole genome array 
CGH (Agilent Human Genome Microarray Array-CGH) 
analysis was performed according to manufacturer’s 
protocol (Agilent Technologies, Paolo Alto CA) and the 
search for Copy Number Variation Regions (CNVRs) was 
performed using the Database of Genomic Variants (http://
projects.tcag.ca/variation/).
Somatic mutation analysis
Mutation detection research was performed using 
qBiomarker Somatic Mutation PCR Arrays (Qiagen); each 
array is comprised of a custom panel of gene mutations, 
including TP53, ASXL1, EZH2, TET2, RUNX1, DNMT3A 
and SF3B1 genes, selected from comprehensive somatic 
mutation databases (COSMIC). The assay was established 
in a RT-PCR based on Amplification Refractory Mutation 
System (ARMS) technology. The panel included: a) 
seventeen different TP53 gene mutations comprised on 
DNA binding domain and ranged from 163 to 285 aa; 
b) three different ASXL1 gene mutations comprised on 
exon 12 and two frame-shift mutations in SCR1 binding 
domain; c) three EZH2 gene mutations located in the 
SET domain, d) two TET2 gene mutations comprised on 
exon 3, e) seven RUNX1 gene mutations identified in 
exons 3, 4 and 6, f) two DNMT3A gene mutations into 
methyltransferase domain and g) three different SF3B1 
gene mutations clustered in the HEAT domain repeats 
(HD).
WT1 and RPS14 gene expression analysis
After RNA extraction from bone marrow blood 
samples using RNeasy Mini Kit (QIAGEN, Valencia, CA, 
USA) and the cDNA synthesis performed using about 1 ug 
of RNA according to manufacturer’s protocol (Invitrogen, 
Thermo Fisher Scientific, Massachusetts, USA), different 
RT-PCR quantification analysis were performed for WT1 
and RPS14 genes.
The WT1 gene expression analysis were assessed by 
the “WT1 ProfileQuant® kit (ELN)” (Ipsogen, Marseille, 
France), whose components have been tested in the 
context of a collaborative study of the European Leukemia 
Net consortium (ELN) and selected as the ELN WT1 
assay. On the contrary, the RT-PCR quantitative assays for 
RPS14 gene was performed using separated amplification 
of target gene and of 18S gene as endogenous control. In 
each reaction were assessed standard serial dilutions of 
control gene and RPS14 plasmids, using a commercial kit 
primers design (Eppendorf). Moreover, cDNA samples 
from five 5q- syndromes and 6 healthy donors (patients 
aged 60-70 years who underwent femur surgery) will be 
used as positive and negative controls respectively.
Statistical analysis
Overall Survival (OS) was calculated from the time 
of diagnosis to the last visit or follow-up or death; patients 
were censored at the moment of death or just before the 
allogeneic transplantation (in two cases).
Time to event variables (OS and progression-free-
survival or PFS) are presented as Kaplan-Meier plots of 
time to first event.
Response rates will be expressed as percentages 
with their 95% Exact Clopper Pearson Confidence Interval 
limits. T-test has been employed for comparing median 
and mean values for continuous numerical variables. 
To determine significances in categorized variables, 
SPSS 17.0 (SPSS Inc, Chicago, IL, USA) was used 
to calculate Pearson Chi-square or Fisher’s exact test, 
when appropriate. All tests were 2-sided. Results were 
considered statistically significant for p≤0.05.
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